Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Zai Lab stock

Own Zai Lab stock in just a few minutes.

Zai Lab Limited is a biotechnology business based in the US. Zai Lab shares (ZLAB) are listed on the NASDAQ and all prices are listed in US Dollars. Zai Lab employs 1,194 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Zai Lab

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ZLAB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Zai Lab share price

Use our graph to track the performance of ZLAB stocks over time.

Zai Lab shares at a glance

Information last updated 2021-03-10.
52-week range$43.06 - $193.54
50-day moving average $166.09
200-day moving average $117.17
Wall St. target price$174.24
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.12

Buy Zai Lab shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Zai Lab stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zai Lab financials

Revenue TTM $49 million
Gross profit TTM $32.2 million
Return on assets TTM -22.83%
Return on equity TTM -36.74%
Profit margin 0%
Book value $13.32
Market capitalisation $11.1 billion

TTM: trailing 12 months

Shorting Zai Lab shares

There are currently 1.5 million Zai Lab shares held short by investors – that's known as Zai Lab's "short interest". This figure is 10.3% down from 1.6 million last month.

There are a few different ways that this level of interest in shorting Zai Lab shares can be evaluated.

Zai Lab's "short interest ratio" (SIR)

Zai Lab's "short interest ratio" (SIR) is the quantity of Zai Lab shares currently shorted divided by the average quantity of Zai Lab shares traded daily (recently around 351800.96153846). Zai Lab's SIR currently stands at 4.16. In other words for every 100,000 Zai Lab shares traded daily on the market, roughly 4160 shares are currently held short.

However Zai Lab's short interest can also be evaluated against the total number of Zai Lab shares, or, against the total number of tradable Zai Lab shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zai Lab's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Zai Lab shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Zai Lab shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zai Lab.

Find out more about how you can short Zai Lab stock.

Zai Lab share dividends

We're not expecting Zai Lab to pay a dividend over the next 12 months.

Zai Lab share price volatility

Over the last 12 months, Zai Lab's shares have ranged in value from as little as $43.06 up to $193.54. A popular way to gauge a stock's volatility is its "beta".

ZLAB.US volatility(beta: 1.14)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zai Lab's is 1.1394. This would suggest that Zai Lab's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Zai Lab overview

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, autoimmune, and infectious diseases in China. The company offers Niraparib, an oral small molecule poly ADP ribose polymerase 1/2 inhibitor for the treatment of multiple solid tumors, including ovarian and other types of lung cancer; and Optune, a cancer therapy for the treatment of glioblastoma multiforme. It also develops Ripretinib, a switch control inhibitor for the treatment of KIT and/or PDGFRa-driven cancers, including gastrointestinal stromal tumors, systemic mastocytosis, and other cancers; REGN1979 for the treatment of diffuse large B-cell lymphoma and follicular lymphoma; Margetuximab an immune-optimized anti-HER2 monoclonal antibody for the treatment of breast and gastric cancers; and INCMGA0012, an investigational monoclonal antibody for the treatment of MSI-high endometrial cancer. In addition, the company develops Bemarituzumab, a humanized monoclonal antibody for the treatment of gastric and gastroesophageal cancers; Omadacycline, an antibiotic to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections; and Durlobactam for the treatment of acinetobacter baumannii bacterial infections. Zai Lab Limited has license and collaboration agreements with the TESARO Inc. ; Paratek Bermuda, Ltd. ; Five Prime Therapeutics, Inc.

Frequently asked questions

What percentage of Zai Lab is owned by insiders or institutions?
Currently 1.182% of Zai Lab shares are held by insiders and 70.218% by institutions.
How many people work for Zai Lab?
Latest data suggests 1,194 work at Zai Lab.
When does the fiscal year end for Zai Lab?
Zai Lab's fiscal year ends in December.
Where is Zai Lab based?
Zai Lab's address is: Building 1, Jinchuang Plaza, Shanghai, China, 201210
What is Zai Lab's ISIN number?
Zai Lab's international securities identification number is: US98887Q1040
What is Zai Lab's CUSIP number?
Zai Lab's Committee on Uniform Securities Identification Procedures number is: 894789106

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site